YouTube Facebook LinkedIn Google+ Twitter Xinginstagram rss  


BOULDER, CO, UNITED STATES - May 14, 2014 - Array BioPharma Inc. (NASDAQ: ARRY) today announced presentations on its MEK inhibitors, binimetinib (MEK162) (co-developing with Novartis) and selumetinib (licensed to AstraZeneca) at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 30 - June 3, 2014 in Chicago, Illinois.  Both MEK inhibitors are advancing in Phase 3 or pivotal trials:  binimetinib is being evaluated in NRAS- and BRAF-mutant melanoma and low-grade serous ovarian cancer.  In addition, selumetinib is being evaluated in non-small cell lung cancer, uveal melanoma and thyroid cancer. 

Ron Squarer, Chief Executive Officer of Array, noted, “We are encouraged to see six ASCO abstracts reporting clinical results for our two partnered MEK programs, while steady progress continues across the pivotal trials for these programs.”

The following is a summary of the presentations that will be given at ASCO:


Oral Presentation

Title:         A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity (Abstract #9009)

Presenter:             Jeffrey Alan Sosman, MD

Date:                     Sunday, June 1, 8:24 - 8:36 a.m. CDT (Oral Presentation)


Poster Presentations

Title:         A phase 1b dose escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors (Abstract #9051)

Presenter:             Dejan Juric, MD

Date:                     Saturday, May 31, 8 - 11:45 a.m. CDT


Title:                     Effect of the BRAF inhibitor LGX818 on endoplasmic reticulum stress and sensitivity of NRAS-mutant melanoma cells to the MEK inhibitor binimetinib (Abstract #9062)

Presenter:             Friedegund Elke Meier, Prof. Dr. med.

Date:                     Saturday, May 31, 8 - 11:45 a.m. CDT


Title:                     ABC-04: A phase 1b trial of cisplatin, gemcitabine and selumetinib in patients with advanced biliary tract cancers (Abstract #4090)

Presenter:             John A. Bridgewater, MD

Date:                     Saturday, May 31, 8 - 11:45 a.m. CDT


Title:                     Phenformin combines with selumetinib in targeting KRAS mutant non-small cell lung cancer cells with alternative LKB1 status (Abstract #2589)

Presenter:             Jun Zhang, MD, Ph.D.

Date:                     Sunday, June 1, 8 - 11:45 a.m. CDT


Title:                     The Role of MEK inhibition in Neuroblastoma Tumor Cells (Abstract #10068)       

Presenter:             Avinash Gupta, MBBS BSc MRCP

Date:                     Monday, June 2, 8 - 11:45 a.m. CDT


Title:                     Phase I Study of the MEK1/2 inhibitor selumetinib (AZD6244 hydrogen sulfate) in children and young adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs) (Abstract #10018)

Presenter:             Brigitte C. Widemann, MD

Date:                     Monday, June 2, 8 a.m. - 11:45 a.m. CDT


Title:                     A phase 1 study of AZD6244 in children with recurrent or refractory low-grade gliomas: A Pediatric Brain Tumor Consortium report (Abstract #10065)

Presenter:             Anuradha Banerjee, MD

Date:                     Monday, June 2, 8 a.m. - 11:45 a.m. CDT


Title:                     NCI #8412: A randomized phase II trial of AZD6244 alone and AZD6244 plus temsirolimus for soft-tissue sarcomas  (Abstract #10526)

Presenter:             Zeynep Eroglu, MD

Date:                     Tuesday, June 3, 8 - 11:00 a.m. CDT


Trials in Progress posters will also showcase the trial designs for the binimetinib trials in low-grade serous ovarian cancer (MILO) and NRAS mutant melanoma (NEMO). 

ASCO’s embargo for abstracts in this release will lift on Wednesday, May 14 at 6:00 p.m. EDT.  All abstracts can be accessed through the ASCO website,  After the presentations and posters are public, they will be available as PDFs on Array's website at


About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer.  Seven Phase 3 or pivotal studies are already in progress, or are planned to begin this year. These programs include the wholly-owned hematology drug, filanesib (ARRY-520) for multiple myeloma and two partnered cancer drugs, selumetinib (AstraZeneca) and binimetinib (MEK162 / Novartis).  For more information on Array, please go to



Tricia Haugeto

(303) 386-1193


Click here to login and leave a comment.  


Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact Angela Parsons, 781.972.5467.